Latest STOPCAP results presented at the Advanced Prostate Cancer Consensus Conference (APCCC) 2026
News
Latest STOPCAP results presented at ASCO GU 2025
Our latest STOPCAP results presented at ASCO GU 2025
New prostate cancer treatments could reach men sooner
New results from STOPCAP show that better prostate cancer treatments could reach men almost two years sooner than is currently possible.
Which people with metastatic prostate cancer benefit most from upfront docetaxel?
Which people with metastatic prostate cancer benefit most from upfront docetaxel?
New results from our first STOPCAP M1 individual participant data meta-analysis have been published in The Lancet Oncology and show that adding docetaxel to hormone therapy is more beneficial for some people with advanced prostate cancer than others.
2022 STOPCAP M1 Collaborators meeting
Once again, we held a STOPCAP M1 Colloborators Meeting to coincide with ESMO. This year...Paris...